They’ve Got Next: The 40 Under 40 - Tara Fisher of Ropes & Gray

Please describe two of your most substantial, recent wins in practice.

Representing ImmunoGen in its sale to AbbVie, which closed earlier this year, was particularly meaningful to me because it means its flagship ovarian cancer drug Elahere has the opportunity to reach even more patients. I know how devastating a diagnosis that can be. I lost one of my oldest and closest friends to ovarian cancer late last year, just a few months shy of her own fortieth birthday. Being part of this transaction was personally meaningful, while also professionally rewarding, during that difficult time.

The sale of ImmunoGen occurred ...